Related Experiment Video
Updated: Jul 11, 2026
06:20
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Optimal phase I dose-escalation trial designs in oncology--a simulation study.
1Department of Nuclear Medicine, Odense University Hospital, Odense C, Denmark. oke@stat.sdu.dk
Statistics in Medicine
|September 13, 2007
Summary
The Bayesian ADEPT method accurately estimates the maximum tolerated dose (MTD) in oncology trials, often requiring fewer patients than traditional methods. While the traditional escalation rule (TER) is safest, ADEPT offers a valuable, quick, and accurate alternative for dose-finding studies.
Area of Science:
- Clinical Pharmacology
- Biostatistics
- Oncology Drug Development
Background:
- Phase I oncology trials traditionally use the maximum tolerated dose (MTD) estimation via the traditional escalation rule (TER).
- Newer methods aim for improved MTD precision and reduced patient numbers compared to TER.
- Evaluating these novel methods against TER is crucial for optimizing early-phase oncology trial design.
Purpose of the Study:
- To compare the accuracy and efficiency of the traditional escalation rule (TER) against several novel dose-escalation designs.
- To assess performance based on MTD estimation accuracy, patient numbers, and toxicity profiles across varying toxicity scenarios.
- To evaluate the utility of Bayesian ADEPT (assisted decision-making in early phase trials) in phase I oncology dose-escalation studies.
Main Methods:
- A simulation study was conducted using 50,000 trials for each design.
- Designs compared included TER, accelerated titration dose design (ATD), biased coin design, r-in-a-row (RIAR), continual reassessment method (CRML), and Bayesian ADEPT.
- Performance metrics included MTD accuracy, average patients per run, and toxicities per run.
Main Results:
- Bayesian ADEPT demonstrated superior accuracy in medium toxicity scenarios and competitive accuracy in low/high toxicity scenarios.
- ADEPT required the fewest patients per run in medium and high toxicity scenarios, while TER was most efficient in low toxicity.
- TER was the safest method (least toxicities) but least accurate; ADEPT was quick and accurate; CRML and up-and-down designs showed no significant advantages.
Conclusions:
- Bayesian ADEPT is a valuable tool for phase I oncology dose-escalation trials, offering a balance of speed and accuracy.
- While TER remains the safest, its accuracy is limited; ADEPT provides a more precise estimation of the MTD.
- Thorough preparation is essential for the successful implementation of Bayesian ADEPT in clinical practice.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...